Log in

C4 Therapeutics Stock Forecast, Price & News

-0.34 (-1.36 %)
(As of 10/30/2020 12:00 AM ET)
Today's Range
Now: $24.75
50-Day Range N/A
52-Week Range
Now: $24.75
Volume274,892 shs
Average Volume822,592 shs
Market Capitalization$1.03 billion
P/E RatioN/A
Dividend YieldN/A
C4 Therapeutics, Inc., a biopharmaceutical company, develops novel therapeutic candidates to target and destroy disease-causing proteins for the treatment of cancer, neurodegenerative conditions, and other diseases. Its lead product candidate is CFT7455, an orally bioavailable degrader targeting IKZF1/3 for multiple myeloma, peripheral T-cell lymphoma, and mantle cell lymphoma. The company is also developing CFT8634, an orally bioavailable degrader of BRD9, a protein target for synovial sarcoma and SMARCB1-deleted solid malignancies; and BRAF V600E and RET programs for genetically defined resistant solid tumors. It has strategic collaborations with F. Hoffman-La Roche Ltd.; Biogen, Inc.; and Calico Life Sciences LLC. C4 Therapeutics, Inc. was founded in 2015 and is headquartered in Watertown, Massachusetts.
Read More

Beat the Market (BTM) Rank

Analyst Opinion: 3.5Community Rank: 0.0Dividend Strength: 0.0Insider Behavior: 3.0Valuation: 0.6 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

1.43 out of 5 stars

Industry, Sector and Symbol

Industry Biological products, except diagnostic
Current SymbolNASDAQ:CCCC



Sales & Book Value

Annual SalesN/A



Market Cap$1.03 billion
Next Earnings DateN/A
OptionableNot Optionable
-0.34 (-1.36 %)
(As of 10/30/2020 12:00 AM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive CCCC News and Ratings via Email

Sign-up to receive the latest news and ratings for CCCC and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles

C4 Therapeutics (NASDAQ:CCCC) Frequently Asked Questions

Do Wall Street analysts recommend investors buy shares of C4 Therapeutics?

3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for C4 Therapeutics in the last year. There are currently 3 buy ratings for the stock, resulting in a consensus recommendation of "Buy."
View analyst ratings for C4 Therapeutics

What price target have analysts set for CCCC?

3 Wall Street analysts have issued 12-month price objectives for C4 Therapeutics' stock. Their forecasts range from $33.00 to $34.00. On average, they anticipate C4 Therapeutics' stock price to reach $33.50 in the next year. This suggests a possible upside of 35.4% from the stock's current price.
View analysts' price targets for C4 Therapeutics

Who are some of C4 Therapeutics' key competitors?

Who are C4 Therapeutics' key executives?

C4 Therapeutics' management team includes the following people:
  • Mr. Marc A. Cohen, Co-Founder, Exec. Chairman, CEO, Sec. & Treasurer (Age 57)
  • Mr. Andrew Hirsch, CEO, Pres & Director (Age 49)
  • Dr. Kenneth C. Anderson, Co-Founder & Independent Director (Age 69)
  • Dr. Nathanael S. Gray Ph.D., Co-Founder and Member of Scientific Advisory Board
  • Mr. William T. McKee, Chief Financial Officer (Age 58)

When did C4 Therapeutics IPO?

(CCCC) raised $150 million in an IPO on Friday, October 2nd 2020. The company issued 8,800,000 shares at a price of $16.00-$18.00 per share. Jefferies, Evercore ISI, BMO Capital Markets and UBS Investment Bank served as the underwriters for the IPO.

What is C4 Therapeutics' stock symbol?

C4 Therapeutics trades on the NASDAQ under the ticker symbol "CCCC."

When does C4 Therapeutics' quiet period expire?

C4 Therapeutics' quiet period expires on Wednesday, November 11th. C4 Therapeutics had issued 9,600,000 shares in its public offering on October 2nd. The total size of the offering was $182,400,000 based on an initial share price of $19.00. During C4 Therapeutics' quiet period, underwriters and any insiders that worked on the IPO are prevented from issuing any research reports for the company because of SEC regulations. Following the end of the company's quiet period, it's expected that the brokerages that served as underwriters on the stock will initiate research coverage on the company.

How do I buy shares of C4 Therapeutics?

Shares of CCCC can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is C4 Therapeutics' stock price today?

One share of CCCC stock can currently be purchased for approximately $24.75.

How big of a company is C4 Therapeutics?

C4 Therapeutics has a market capitalization of $1.03 billion. C4 Therapeutics employs 88 workers across the globe.

What is C4 Therapeutics' official website?

The official website for C4 Therapeutics is www.c4therapeutics.com.

How can I contact C4 Therapeutics?

The company can be reached via phone at 617-231-0700.

This page was last updated on 10/31/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.